Dec
New Lung Cancer Therapy Fights Deadly Disease
A new oral prescription medication that is being studied in an international clinical trial now it Phase III may be a successful alternative to chemotherapy, according to news results.
The trial was developed and studied by scientists at the University of Texas M.D. Anderson Cancer Center and studied approximately 1,466 patients suffering from lung cancer in 24 various countries worldwide. Patients participated in receiving randomized treatments of Iressa, a once-daily tablet, or docetaxel, which is a form of chemotherapy.
Those receiving chemotherapy had a combined median survival rate of 8 months with 34 percent having a one-year survival rate. Similarly, patients given the Iressa treatment had an overall survival rate of 7.6 months with a 32 percent survival rate of one year.